Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 18/20 | 0.62 |
| ▸ | MMP3 | P08254 | 14/20 | 0.62 |
| ▸ | MMP13 | P45452 | 14/20 | 0.62 |
| ▸ | MMP1 | P03956 | 13/20 | 0.62 |
| ▸ | MMP9 | P14780 | 13/20 | 0.61 |
| ▸ | MMP7 | P09237 | 11/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MMP14 | P50281 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768748 | 0.86 | MMP2 (0.57) | MMP2MMP3MMP13MMP1MMP9 | |
| SCHEMBL7945709 | 0.85 | MMP2 (0.54) | MMP2MMP3MMP13MMP1MMP9 | |
| SCHEMBL14191410 | 0.84 | RECQL (0.63) | MMP2MMP3MMP13MMP1MMP9 | |
| SCHEMBL14514554 | 0.83 | ALDH1A1 (0.53) | MMP2MMP3MMP13MMP1MMP9 | |
| SCHEMBL8049244 | 0.83 | ALDH1A1 (0.53) | MMP2MMP3MMP13MMP1MMP9 | |
| SCHEMBL6774654 | 0.82 | MMP2 (0.53) | MMP2MMP3MMP13MMP1MMP9 | |
| SCHEMBL14191408 | 0.82 | MMP2 (0.74) | MMP2MMP3MMP13MMP1MMP9 | |
| SCHEMBL5639380 | 0.82 | MMP2 (0.57) | MMP2MMP3MMP13MMP1MMP9 | |
| SCHEMBL1737163 | 0.81 | POLB (0.51) | MMP2MMP3MMP13MMP1MMP9 | |
| SCHEMBL1735671 | 0.81 | POLB (0.51) | MMP2MMP3MMP13MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223751-B2 | Sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same | KOLON IND. INC. (KR) | 2007-05-29 | — | — | US | disclosed |
| EP-1389204-A4 | NOVEL SULFONAMIDE DERIVATIVES, INTERMEDIATE THEREOF, ITS PREPARATION METHODS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOLON INC (KR) | 2005-03-23 | — | — | EP | disclosed |
| US-20040138206-A1 | Novel sulfonamide derivatives, intermidiate thereof, its preparation methods, and pharmaceutical composition comprising the same | KOLON LIFE SCIENCE, INC. (KR) | 2004-07-15 | — | — | US | disclosed |
| EP-1389204-A1 | NOVEL SULFONAMIDE DERIVATIVES, INTERMEDIATE THEREOF, ITS PREPARATION METHODS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Kolon Ind. Inc. (KR) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002088115-A1 | NOVEL SULFONAMIDE DERIVATIVES, INTERMEDIATE THEREOF, ITS PREPARATION METHODS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOLON IND. INC. (KR) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138206-A1 | Novel sulfonamide derivatives, intermidiate thereof, its preparation methods, and pharmaceutical composition comprising the same | MMP1, MMP7, STS | MMP2 19/4885MMP3 20/4885MMP13 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.